Patient characteristics
Patient no. . | Age, y . | Sex . | Ig type . | Therapeutic history . | 13q status by FISH . |
---|---|---|---|---|---|
1 | 66 | M | IgG,λ | ID, IEV, Hd-Mel | ND |
2 | 66 | M | IgG,κ | VAD | Del |
3 | 45 | F | κ | VAD, IEV, Hd-Mel | Del |
4 | 57 | F | NS | VAD, IEV, Hd-Mel | Del |
5 | 61 | M | IgG,λ | D, IEV, Hd-Mel | Nor |
6 | 58 | F | IgG,κ | VAD, IEV, Hd-Mel | Del |
7 | 70 | M | IgG,λ | D, IEV, T-Hd-Mel | ND |
8 | 63 | F | IgG,κ | VAD, AD | Nor |
9 | 42 | M | IgG,κ | ID, IEV, Hd-Mel | Nor |
10 | 61 | M | IgG | ID, Mel, VCAP, BP, Bort | ND |
11 | 41 | F | IgG,λ | VAD | Nor |
12 | 68 | M | IgG,κ | MP, B, D, VAD | ND |
13 | 66 | M | IgG,κ | MP, VAD, CC5013 + D | ND |
14 | 65 | F | IgG | MP, Thal + D | ND |
15 | 61 | M | κ | Untreated | ND |
16 | 53 | F | IgG,λ | VAD | Del |
17 | 81 | F | IgG,λ | Untreated | ND |
18 | 64 | M | IgG,κ | ID, IEV, T-Hd-Mel, TamD | ND |
19 | 74 | M | IgG,κ | MP, D, Thal | ND |
20 | 68 | M | NS | D, VAD, D, Hd-Mel | ND |
21 | 60 | M | IgG,λ | VAD, IEV, Hd-Mel | Nor |
22 | 59 | F | IgG,λ | VAD, IEV, Hd-Mel | ND |
23 | 65 | M | IgG,κ | D | ND |
24 | 59 | M | IgG,κ | MP, VBAP, CC5013 + D | ND |
25 | 65 | F | IgG,κ | VAD, IEV, T-Hd-Mel, D, Bort | ND |
Patient no. . | Age, y . | Sex . | Ig type . | Therapeutic history . | 13q status by FISH . |
---|---|---|---|---|---|
1 | 66 | M | IgG,λ | ID, IEV, Hd-Mel | ND |
2 | 66 | M | IgG,κ | VAD | Del |
3 | 45 | F | κ | VAD, IEV, Hd-Mel | Del |
4 | 57 | F | NS | VAD, IEV, Hd-Mel | Del |
5 | 61 | M | IgG,λ | D, IEV, Hd-Mel | Nor |
6 | 58 | F | IgG,κ | VAD, IEV, Hd-Mel | Del |
7 | 70 | M | IgG,λ | D, IEV, T-Hd-Mel | ND |
8 | 63 | F | IgG,κ | VAD, AD | Nor |
9 | 42 | M | IgG,κ | ID, IEV, Hd-Mel | Nor |
10 | 61 | M | IgG | ID, Mel, VCAP, BP, Bort | ND |
11 | 41 | F | IgG,λ | VAD | Nor |
12 | 68 | M | IgG,κ | MP, B, D, VAD | ND |
13 | 66 | M | IgG,κ | MP, VAD, CC5013 + D | ND |
14 | 65 | F | IgG | MP, Thal + D | ND |
15 | 61 | M | κ | Untreated | ND |
16 | 53 | F | IgG,λ | VAD | Del |
17 | 81 | F | IgG,λ | Untreated | ND |
18 | 64 | M | IgG,κ | ID, IEV, T-Hd-Mel, TamD | ND |
19 | 74 | M | IgG,κ | MP, D, Thal | ND |
20 | 68 | M | NS | D, VAD, D, Hd-Mel | ND |
21 | 60 | M | IgG,λ | VAD, IEV, Hd-Mel | Nor |
22 | 59 | F | IgG,λ | VAD, IEV, Hd-Mel | ND |
23 | 65 | M | IgG,κ | D | ND |
24 | 59 | M | IgG,κ | MP, VBAP, CC5013 + D | ND |
25 | 65 | F | IgG,κ | VAD, IEV, T-Hd-Mel, D, Bort | ND |
FISH indicates fluorescence in situ hybridization; ID, idarubicin/dexamethasone; IEV, ifosfamide/epirubicin/etoposide; Hd-Mel, high-dose melphalan; ND, not determined; VAD, vincristine/Adriamycin/dexamethasone; Del, deleted; NS, nonsecretory; D, dexamethasone; Nor, normal; T-Hd-Mel, tandem high-dose melphalan; AD, Adriamycin/dexamethasone; Mel, melphalan; VCAP, vincristine/cyclophosphamide/Adriamycin/prednisone; BP, bendamustine/prednisone; Bort, bortezomib; MP, melphalan/prednisone; B, bendamustine; CC-5013: lenalidomide; Thal, thalidomide; TamD, tamoxifen/dexamethasone; VBAP, vincristine/bendamustine/Adriamycin/prednisone.